ScoutQuest5 Nov 2026
Senores Pharmaceuticals544319Earnings call transcript

Q2 & H1FY27 call transcript: management reaffirms FY27 growth guidance

Senores Pharmaceuticals shared the transcript of its Q2 & H1FY27 earnings call held on October 29, 2026.

By ScoutQuest · · 2 min read

INR67 crores
Q2 FY27INR36.6 croresH1 FY27INR67 crores
Profit after tax: INR36.6 crores (Q2 FY27) and INR67 crores (H1 FY27).
Q2 Revenue
INR192 crores
Q2 EBITDA / PAT
EBITDA INR58 crores, PAT INR36.6 crores
FY27 Guidance
30% to 40% revenue growth and 50% to 60% PAT growth

Senores Pharmaceuticals has shared the transcript of its Q2 & H1FY27 earnings conference call held on October 29, 2026. The call was addressed by Promoter and Managing Director Swapnil Shah, Chairman Sanjay Majmudar, and Whole-time Director and Chief Financial Officer Deval Shah.

Q2 FY27 numbers

H1 FY27 numbers

Cash generation

Guidance given on the call

Products and markets

Manufacturing

Points to keep in mind

More numbers
  • Q2 FY27 revenue from operationsINR192 crores
  • Q2 FY27 EBITDAINR58 crores
  • Q2 FY27 profit after taxINR36.6 crores
  • H1 FY27 revenueINR372.5 crores
  • H1 FY27 profit after taxINR67 crores
  • H1 FY27 operating cash flowINR38 crores
  • FY27 revenue growth guidance30% to 40%
  • FY27 PAT growth guidance50% to 60%
Source: BSE · 5 Nov 2026

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev